{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Intermediate+dose&page=15",
    "query": {
      "intervention": "Intermediate dose",
      "page": 15
    },
    "page_size": 10
  },
  "pagination": {
    "page": 15,
    "page_size": 10,
    "total_count": 2633,
    "total_pages": 264,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Intermediate+dose&page=16&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Intermediate+dose&page=14&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-25T02:26:23.099Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03308942",
      "title": "Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Neoplasms"
      ],
      "interventions": [
        {
          "name": "Niraparib",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "TSR-042 (Dostarlimab)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Tesaro, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 53,
      "start_date": "2017-09-29",
      "completion_date": "2021-08-31",
      "has_results": true,
      "last_update_posted_date": "2023-10-16",
      "last_synced_at": "2026-10-25T02:26:23.099Z",
      "location_count": 16,
      "location_summary": "Whittier, Alaska • Port Saint Lucie, Florida • Atlanta, Georgia + 13 more",
      "locations": [
        {
          "city": "Whittier",
          "state": "Alaska"
        },
        {
          "city": "Port Saint Lucie",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Harvey",
          "state": "Illinois"
        },
        {
          "city": "Tinley Park",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03308942"
    },
    {
      "nct_id": "NCT03624062",
      "title": "MER3101: MAS-1 Adjuvanted Antigen-specific Immunotherapeutic for Prevention and Treatment of Type 1 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Type 1 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "MAS-1 adjuvanted Insulin B-chain",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Colorado, Denver",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 21,
      "start_date": "2020-08-31",
      "completion_date": "2025-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-02-13",
      "last_synced_at": "2026-10-25T02:26:23.099Z",
      "location_count": 1,
      "location_summary": "Aurora, Colorado",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03624062"
    },
    {
      "nct_id": "NCT00846586",
      "title": "Efficacy and Safety of Indacaterol Plus Tiotropium Versus Tiotropium Alone in Patients With Chronic Obstructive Pulmonary Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Obstructive Pulmonary Disease (COPD)"
      ],
      "interventions": [
        {
          "name": "Indacaterol 150 μg",
          "type": "DRUG"
        },
        {
          "name": "Tiotropium 18 μg",
          "type": "DRUG"
        },
        {
          "name": "Placebo to indacaterol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 1134,
      "start_date": "2009-03",
      "completion_date": "2010-03",
      "has_results": true,
      "last_update_posted_date": "2011-08-18",
      "last_synced_at": "2026-10-25T02:26:23.099Z",
      "location_count": 61,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Scottsdale, Arizona + 53 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00846586"
    },
    {
      "nct_id": "NCT00790062",
      "title": "Oxytocin Regimen to Prevent Atony and Postpartum Hemorrhage During Vaginal Delivery: 3-arm RCT",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Uterine Atony",
        "Postpartum Hemorrhage"
      ],
      "interventions": [
        {
          "name": "Oxytocin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Alabama at Birmingham",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "Female only"
      },
      "enrollment_count": 1798,
      "start_date": "2008-11",
      "completion_date": "2010-06",
      "has_results": true,
      "last_update_posted_date": "2016-04-08",
      "last_synced_at": "2026-10-25T02:26:23.099Z",
      "location_count": 1,
      "location_summary": "Birmingham, Alabama",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00790062"
    },
    {
      "nct_id": "NCT04855773",
      "title": "Comparing Mobile Health Strategies to Improve Pre-exposure Prophylaxis Use (PrEP) for HIV Prevention",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "HIV Infections",
        "Sexually Transmitted Diseases"
      ],
      "interventions": [
        {
          "name": "PrEPmate",
          "type": "OTHER"
        },
        {
          "name": "Dot Diary",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DEVICE"
      ],
      "sponsor": "Public Health Foundation Enterprises, Inc.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "15 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "15 Years and older"
      },
      "enrollment_count": 300,
      "start_date": "2021-07-21",
      "completion_date": "2023-08",
      "has_results": false,
      "last_update_posted_date": "2022-09-28",
      "last_synced_at": "2026-10-25T02:26:23.099Z",
      "location_count": 4,
      "location_summary": "San Francisco, California • Washington D.C., District of Columbia • Miami, Florida",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04855773"
    },
    {
      "nct_id": "NCT00785213",
      "title": "Drug-Drug Interaction Study Between Quinine Sulfate and Rosiglitazone",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Rosiglitazone 4 mg Tablets",
          "type": "DRUG"
        },
        {
          "name": "Quinine Sulfate 324 mg Capsules",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mutual Pharmaceutical Company, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 23,
      "start_date": "2008-09",
      "completion_date": "2008-10",
      "has_results": true,
      "last_update_posted_date": "2012-08-07",
      "last_synced_at": "2026-10-25T02:26:23.099Z",
      "location_count": 1,
      "location_summary": "East Grand Forks, Minnesota",
      "locations": [
        {
          "city": "East Grand Forks",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00785213"
    },
    {
      "nct_id": "NCT02781480",
      "title": "Clinical Trial of Gene Therapy for the Treatment of Leber Congenital Amaurosis (LCA)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Leber Congenital Amaurosis"
      ],
      "interventions": [
        {
          "name": "AAV RPE65",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "MeiraGTx UK II Ltd",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "3 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2016-04",
      "completion_date": "2018-12",
      "has_results": true,
      "last_update_posted_date": "2021-07-12",
      "last_synced_at": "2026-10-25T02:26:23.099Z",
      "location_count": 1,
      "location_summary": "Ann Arbor, Michigan",
      "locations": [
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02781480"
    },
    {
      "nct_id": "NCT07422480",
      "title": "A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Lower Risk Myelodysplastic Syndromes (LR-MDS) Who Need Regular Blood Transfusions",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Myelodysplastic Syndrome",
        "Anemia"
      ],
      "interventions": [
        {
          "name": "Elritercept",
          "type": "DRUG"
        },
        {
          "name": "Epoetin Alfa",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Takeda",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 300,
      "start_date": "2026-05-21",
      "completion_date": "2033-10-01",
      "has_results": false,
      "last_update_posted_date": "2026-10-19",
      "last_synced_at": "2026-10-25T02:26:23.099Z",
      "location_count": 31,
      "location_summary": "Gilbert, Arizona • Duarte, California • Santa Rosa, California + 26 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Santa Rosa",
          "state": "California"
        },
        {
          "city": "Whittier",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07422480"
    },
    {
      "nct_id": "NCT04131556",
      "title": "A Study Comparing the Pharmacokinetics and Palatability of Two Candidate Pediatric Powder-for-Oral-Suspension Formulations of Maribavir to the Current Maribavir Tablet Formulation Administered in Healthy Adult Participants",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "Maribavir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Shire",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 20,
      "start_date": "2019-10-25",
      "completion_date": "2020-01-06",
      "has_results": true,
      "last_update_posted_date": "2025-09-02",
      "last_synced_at": "2026-10-25T02:26:23.099Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04131556"
    },
    {
      "nct_id": "NCT00651729",
      "title": "Safety Study of Botulinum Toxin Type A for the Treatment of Focal Upper Limb Poststroke Spasticity",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Stroke",
        "Muscle Spasticity"
      ],
      "interventions": [
        {
          "name": "Botulinum Toxin Type A",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Allergan",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 279,
      "start_date": "2003-04",
      "completion_date": "2004-12",
      "has_results": false,
      "last_update_posted_date": "2008-05-28",
      "last_synced_at": "2026-10-25T02:26:23.099Z",
      "location_count": 1,
      "location_summary": "Indianapolis, Indiana",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00651729"
    }
  ]
}